The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial
Abstract
BACKGROUND The Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of Angiox (MATRIX) programme was designed to assess the comparative safety and effectiveness of radial versus femoral access and of bivalirudin versus unfractionated heparin with optional glycoprotein IIb/IIIa inhibitors in patients with the whole spectrum of acute coronary syndrome undergoing invasive management. Here we describe the prespecified final 1-year outcomes of the entire programme. METHODS MATRIX was a programme of three nested, randomised, multicentre, open-label, superiority trials in patients with acute coronary syndrome in 78 hospitals in Italy, the Netherlands, Spain, and Sweden. Patients with ST-elevation myocardial infarction were simultaneously randomly assigned (1:1) before coronary angiography to radial or femoral access and to bivalirudin, with or without post-percutaneous coronary intervention infusion or unfractionated heparin (one-step inclusion). Patients with non-ST-elevation acute coronary syndrome were randomly assigned (1:1) before coronary angiography to radial or femoral access and, only if deemed eligible to percutaneous coronary intervention after angiography (two-step inclusion), entered the antithrombin type and treatment duration programmes. Randomisation sequences were computer generated, blocked, and stratified by intended new or current use of P2Y12 inhibitor (clopidogrel vs ticagrelor or prasugrel), and acute coronary syndrome type (ST-elevation myocardial infarction, troponin-positive, or troponin-negative non-ST-elevation acute coronary syndrome). Bivalirudin was given as a bolus of 0·75 mg/kg, followed immediately by an infusion of 1·75 mg/kg per h until completion of percutaneous coronary intervention. Heparin was given at 70-100 units per kg in patients not receiving glycoprotein IIb/IIIa inhibitors, and at 50-70 units per kg in patients receiving glycoprotein IIb/IIIa inhibitors. Clinical follow-up was done at 30 days and 1 year. Co-primary outcomes for MATRIX access and MATRIX antithrombin type were major adverse cardiovascular events, defined as the composite of all-cause mortality, myocardial infarction, or stroke up to 30 days; and net adverse clinical events, defined as the composite of non-coronary artery bypass graft-related major bleeding, or major adverse cardiovascular events up to 30 days. The primary outcome for MATRIX treatment duration was the composite of urgent target vessel revascularisation, definite stent thrombosis, or net adverse clinical events up to 30 days. Analyses were done according to the intention-to-treat principle. This trial is registered with ClinicalTrials.gov, number NCT01433627. FINDINGS Between Oct 11, 2011, and Nov 7, 2014, we randomly assigned 8404 patients to receive radial (4197 patients) or femoral (4207 patients) access. Of these 8404 patients, 7213 were included in the MATRIX antithrombin type study and were randomly assigned to bivalirudin (3610 patients) or heparin (3603 patients). Patients assigned to bivalirudin were included in the MATRIX treatment duration study, and were randomly assigned to post-procedure infusion (1799 patients) or no post-procedure infusion (1811 patients). At 1 year, major adverse cardiovascular events did not differ between patients assigned to radial access compared with those assigned to femoral access (14·2% vs 15·7%; rate ratio 0·89, 95% CI 0·80-1·00; p=0·0526), but net adverse clinical events were fewer with radial than with femoral access (15·2% vs 17·2%; 0·87, 0·78-0·97; p=0·0128). Compared with heparin, bivalirudin was not associated with fewer major adverse cardiovascular (15·8% vs 16·8%; 0·94, 0·83-1·05; p=0·28) or net adverse clinical events (17·0% vs 18·4%; 0·91, 0·81-1·02; p=0·10). The composite of urgent target vessel revascularisation, stent thrombosis, or net adverse clinical events did not differ with or without post-procedure bivalirudin infusion (17·4% vs 17·4%; 0·99, 0·84-1·16; p=0·90). INTERPRETATION In patients with acute coronary syndrome, radial access was associated with lower rates of net adverse clinical events compared with femoral access, but not major adverse cardiovascular events at 1 year. Bivalirudin with or without post-procedure infusion was not associated with lower rates of major adverse cardiovascular events or net adverse clinical events. Radial access should become the default approach in acute coronary syndrome patients undergoing invasive management. FUNDING Italian Society of Invasive Cardiology, The Medicines Company, Terumo, amd Canada Research Chairs Programme.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ibanez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., Caforio, A. L. P., Crea, F., Goudevenos, J. A., Halvorsen, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx393 · Cited by 9,728
Self-citationRoffi, M., Patrono, C., Collet, J.-P., Mueller, C., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv320 · Cited by 8,261
Self-citationClinical End Points in Coronary Stent Trials: A Case for Standardized Definitions
Cutlip, D. E., Windecker, S., Mehran, R., Boam, A., Cohen, D. J., van Es, G.-A., Gabriel Steg, P., Morel, M.-A., Mauri, L., Vranckx, P., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.685313 · Cited by 5,497
Self-citationValgimigli, M., Bueno, H., Byrne, R. A., Collet, J.-P., Costa, F., Jeppsson, A., Jüni, P., Kastrati, A., Kolh, P., Mauri, L., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx419 · Cited by 2,987
Self-citationJolly, S. S., Yusuf, S., Cairns, J., Niemelä, K., Xavier, D., Widimsky, P., Budaj, A., Niemelä, M., Valentin, V., Lewis, B. S., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60404-2 · Cited by 2,125
Valgimigli, M., Gagnor, A., Calabró, P., Frigoli, E., Leonardi, S., Zaro, T., Rubartelli, P., Briguori, C., Andò, G., Repetto, A., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60292-6 · Cited by 1,303
Self-citationShahzad, A., Kemp, I., Mars, C., Wilson, K., Roome, C., Cooper, R., Andron, M., Appleby, C., Fisher, M., Khand, A., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60924-7 · Cited by 543
Ferrante, G., Rao, S. V., Jüni, P., Da Costa, B. R., Reimers, B., Condorelli, G., Anzuini, A., Jolly, S. S., Bertrand, O. F., Krucoff, M. W., et al. (2016) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2016.04.014 · Cited by 524
Self-citationBivalirudin Started during Emergency Transport for Primary PCI
Steg, P. G., van 't Hof, A., Hamm, C. W., Clemmensen, P., Lapostolle, F., Coste, P., Ten Berg, J., Van Grunsven, P., Eggink, G. J., Nibbe, L., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1311096 · Cited by 498
Self-citationStone, G. W., Witzenbichler, B., Guagliumi, G., Peruga, J. Z., Brodie, B. R., Dudek, D., Kornowski, R., Hartmann, F., Gersh, B. J., Pocock, S. J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60764-2 · Cited by 452
Cited by
Collet, J.-P., Thiele, H., Barbato, E., Barthélémy, O., Bauersachs, J., Bhatt, D. L., Dendale, P., Dorobantu, M., Edvardsen, T., Folliguet, T., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa575 · Cited by 5,037
Self-citationRao, S. V., O’Donoghue, M. L., Ruel, M., Rab, T., Tamis-Holland, J. E., Alexander, J. H., Baber, U., Baker, H., Cohen, M. G., Cruz-Ruiz, M., et al. (2025) · Circulation · doi:10.1161/cir.0000000000001309 · Cited by 625
2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes
Rao, S. V., O’Donoghue, M. L., Ruel, M., Rab, T., Tamis-Holland, J. E., Alexander, J. H., Baber, U., Baker, H., Cohen, M. G., Cruz-Ruiz, M., et al. (2025) · JACC · doi:10.1016/j.jacc.2024.11.009 · Cited by 552
Metadata
- Authors
- Valgimigli, M., Frigoli, E., Leonardi, S., Vranckx, P., Rothenbühler, M., Tebaldi, M., Varbella, F., Calabrò, P., Garducci, S., Rubartelli, P., Briguori, C., Andó, G., Ferrario, M., Limbruno, U., Garbo, R., Sganzerla, P., Russo, F., Nazzaro, M., Lupi, A., Cortese, B., Ausiello, A., Ierna, S., Esposito, G., Ferrante, G., Santarelli, A., Sardella, G., de Cesare, N., Tosi, P., van 't Hof, A., Omerovic, E., Brugaletta, S., Windecker, S., Heg, D., Jüni, P., Campo, G., Uguccioni, L., Tamburino, C., Presbitero, P., Zavalloni-Parenti, D., Ferrari, F., Ceravolo, R., Tarantino, F., Pasquetto, G., Casu, G., Mameli, S., Stochino, M. L., Mazzarotto, P., Cremonesi, A., Saia, F., Saccone, G., Abate, F., Picchi, A., Violini, R., Colangelo, S., Boccuzzi, G., Guiducci, V., Vigna, C., Zingarelli, A., Gagnor, A., Zaro, T., Tresoldi, S., Vandoni, P., Contarini, M., Liso, A., Dellavalle, A., Curello, S., Mangiacapra, F., Evola, R., Palmieri, C., Falcone, C., Liistro, F., Creaco, M., Colombo, A., Chieffo, A., Perkan, A., De Servi, S., Fischetti, D., Rigattieri, S., Sciahbasi, A., Pucci, E., Romagnoli, E., Moretti, C., Moretti, L., De Caterina, R., Caputo, M., Zimmarino, M., Bramucci, E., Di Lorenzo, E., Turturo, M., Bonmassari, R., Penzo, C., Loi, B., Mauro, C., Petronio, A. S., Gabrielli, G., Micari, A., Belloni, F., Amico, F., Comeglio, M., Fresco, C., Klinieken, I., Van Mieghem, N., Diletti, R., Regar, E., Sabaté, M., Gómez Hospital, J. A., Díaz Fernández, J. F., Mainar, V., & de la Torre Hernandez, J. M.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2018-09
- Volume
- 392
- Issue
- 10150
- Pages
- 835-848
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2888430622
- Cited by
- 310
- References
- 16
- FWCI
- 24.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial. https://app.cochat.ai/papers/10.1016/s0140-6736(18)31714-8
- The paper
- Valgimigli, M., Frigoli, E., Leonardi, S., Vranckx, P., Rothenbühler, M., Tebaldi, M., Varbella, F., Calabrò, P., Garducci, S., Rubartelli, P., Briguori, C., Andó, G., Ferrario, M., Limbruno, U., Garbo, R., Sganzerla, P., Russo, F., Nazzaro, M., Lupi, A., . . . de la Torre Hernandez, J. M. (2018). Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial. The Lancet. https://doi.org/10.1016/s0140-6736(18)31714-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.